<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04675060</url>
  </required_header>
  <id_info>
    <org_study_id>TQ-B3139-I-02</org_study_id>
    <nct_id>NCT04675060</nct_id>
  </id_info>
  <brief_title>Effect of High-fat Meal on the Pharmacokinetics of TQ-B3139 Capsules</brief_title>
  <official_title>A Study of the Effect of High-fat Meal on the Pharmacokinetics of Oral TQ-B3139 Capsules in Patients With Solid Tumor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to evaluate the effect of high-fat meal on the pharmacokinetics of TQ-B3139&#xD;
      capsules in patients with solid tumor&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 23, 2021</start_date>
  <completion_date type="Anticipated">March 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC0-t</measure>
    <time_frame>0hour, 1hour, 2hour, 3hour, 4hour, 5hour, 6hour, 7hour, 8hour, 10hour, 24hour, 48hour,72hour, 96hour on day 1 and day 5.</time_frame>
    <description>To characterize the pharmacokinetics of TQ-B3139 by assessment of area under the plasma concentration time curve from zero to time.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-∞</measure>
    <time_frame>0hour, 1hour, 2hour, 3hour, 4hour, 5hour, 6hour, 7hour, 8hour, 10hour, 24hour, 48hour,72hour, 96hour on day 1 and day 5.</time_frame>
    <description>To characterize the pharmacokinetics of TQ-B3139 by assessment of area under the plasma concentration time curve from zero to infinity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>0hour, 1hour, 2hour, 3hour, 4hour, 5hour, 6hour, 7hour, 8hour, 10hour, 24hour, 48hour,72hour, 96hour on day 1 and day 5.</time_frame>
    <description>Cmax is the maximum plasma concentration of TQ-B3139 or metabolite(s).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>0hour, 1hour, 2hour, 3hour, 4hour, 5hour, 6hour, 7hour, 8hour, 10hour, 24hour, 48hour,72hour, 96hour on day 1 and day 5.</time_frame>
    <description>To characterize the pharmacokinetics of TQ-B3139 by assessment of time to reach maximum plasma concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>0hour, 1hour, 2hour, 3hour, 4hour, 5hour, 6hour, 7hour, 8hour, 10hour, 24hour, 48hour,72hour, 96hour on day 1 and day 5.</time_frame>
    <description>t1/2 is time it takes for the blood concentration of TQ-B3139 or metabolite(s) to drop by half.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Percentage of participants achieving complete response (CR) and partial response (PR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>up to 24 months</time_frame>
    <description>PFS defined as the time from first dose to the first documented progressive disease (PD) or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Percentage of participants achieving Complete Response (CR) and Partial Response (PR) and Stable Disease (SD).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>up to 24 months</time_frame>
    <description>DOR defined as time from earliest date of disease response to earliest date of disease progression based on radiographic assessment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TQ-B3139 capsules administered single dose of 600 mg under fasted conditions in day 1 followed by single dose of 600 mg with a high-fat meal in day 5, then TQ-B3139 capsules administered 600mg orally, twice daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TQ-B3139 capsules administered single dose of 600 mg with a high-fat meal in day 1 followed by single dose of 600 mg under fasted conditions in day 5, then TQ-B3139 capsules administered 600mg orally, twice daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TQ-B3139 capsules</intervention_name>
    <description>TQ-B3139 capsules administered 600mg orally, twice daily in 28-day cycle.</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 to 1.&#xD;
&#xD;
             2. Life expectancy ≥12 weeks. 3. Patients with confirmed gene mutations, including ALK&#xD;
             fusion, ROS1 fusion, MET mutation or amplification.&#xD;
&#xD;
             4. Adequate organ system function. 5.Female patients of childbearing age should agree&#xD;
             to use contraceptive measures during the study period and for at least 6 months after&#xD;
             study is stopped; male patients should agree to use contraception during the study&#xD;
             period and for at least 6 months after study is stopped.&#xD;
&#xD;
             6.Understood and signed an informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Has other malignancies within 3 years. 2. Has multiple factors affecting oral&#xD;
             medication. 3. The toxicity of previous antitumor treatment is not recovered to ≤&#xD;
             grade 1(CTCAE 5.0) .&#xD;
&#xD;
             4. Has received major surgical treatment, open biopsy or obvious traumatic injury&#xD;
             within 28 days before the first dose.&#xD;
&#xD;
             5. Has long-term unhealed wounds or fractures. 6. Has a history of psychotropic drug&#xD;
             abuse or have a mental disorder. 7. Has any severe and/or uncontrolled disease. 8. Has&#xD;
             received surgery, chemotherapy, radiotherapy or other anticancer therapies 4 weeks or&#xD;
             5 half-life of drug elimination (whichever comes first) before the first dose.&#xD;
&#xD;
             9. Has participated in other clinical studies within 4 weeks before enrollment.&#xD;
             10.Using inhibitors or inducers of CYP3A at present. 11. Has receiving Chinese patent&#xD;
             medicines with anti-tumor indications in the drug instructions that NMPA approved&#xD;
             within 2 weeks before the start of the study treatment.&#xD;
&#xD;
             12. Pleural effusion, pericardial effusion or ascites that cannot be controlled and&#xD;
             need repeated drainage.&#xD;
&#xD;
             13. Brain metastases with symptoms or symptoms of brain metastases were controlled for&#xD;
             less than 2 weeks.&#xD;
&#xD;
             14. In lactation period or plan to breastfeed during the study period. 15.According to&#xD;
             the judgement of the researchers, there are other factors that subjects are not&#xD;
             suitable for the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nong Yang, Doctor</last_name>
    <phone>0731-89762320</phone>
    <email>yangnongpi@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hunan Cancer Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nong Yang, Doctor</last_name>
      <phone>0731-89762320</phone>
      <email>yangnongpi@163.com</email>
    </contact>
    <investigator>
      <last_name>Nong Yang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 14, 2020</study_first_submitted>
  <study_first_submitted_qc>December 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2020</study_first_posted>
  <last_update_submitted>March 29, 2021</last_update_submitted>
  <last_update_submitted_qc>March 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

